Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Associations between lifetime classic psychedelic use and cardiometabolic diseases
Otto Simonsson, Walter Osika, Robin Carhart‐Harris, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 33
Psilocybin: From Psychiatric Pariah to Perceived Panacea
Gregory A. Fonzo, Aaron Wolfgang, Bryan Barksdale, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 54-78
Closed Access | Times Cited: 1
Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study
Grant Jones, Matthew K. Nock
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 29
Diminished psychedelic returns on distress: Marital status and household size
Sean M. Viña
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0293675-e0293675
Open Access | Times Cited: 7
Therapeutic modulation of the kynurenine pathway in severe mental illness and comorbidities: A potential role for serotonergic psychedelics
Antonella Campanale, Antonio Inserra, Stefano Comai
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 134, pp. 111058-111058
Open Access | Times Cited: 6
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling
Jack E. Henningfield, Marion A. Coe, Roland R. Griffiths, et al.
Neuropharmacology (2022) Vol. 218, pp. 109220-109220
Open Access | Times Cited: 25
Psychedelics and workplace harm
Sean Matthew Viña, Amanda Layne Stephens
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 13
Minorities’ diminished psychedelic returns: Cardio-metabolic health
Sean Matthew Viña
Drug Science Policy and Law (2024) Vol. 10
Open Access | Times Cited: 5
Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD)
Bryce D. Beutler, Kenneth Shinozuka, Burton J. Tabaac, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 2, pp. e104-e111
Closed Access | Times Cited: 5
Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 2, pp. e97-e103
Closed Access | Times Cited: 5
Psychedelics in the treatment of unipolar and bipolar depression
Oliver G. Bosch, Simon Halm, Erich Seifritz
International Journal of Bipolar Disorders (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 19
Classic psychedelics, health behavior, and physical health
Otto Simonsson, Peter S. Hendricks, Richard Chambers, et al.
Therapeutic Advances in Psychopharmacology (2022) Vol. 12
Open Access | Times Cited: 19
Minorities’ diminished psychedelic returns
Sean M. Viña, Amanda L Stephens
Drug Science Policy and Law (2023) Vol. 9
Open Access | Times Cited: 11
Religion, Psychedelics, Risky Behavior, and Violence
Sean M. Viña
Journal of Psychoactive Drugs (2024), pp. 1-12
Closed Access | Times Cited: 4
Minorities’ Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians
Sean M. Viña
Journal of Racial and Ethnic Health Disparities (2024)
Open Access | Times Cited: 4
Minorities’ Diminished Psychedelic Returns: Gender, Perceived Stigma, and Distress
Sean M. Viña
Psychoactives (2024) Vol. 3, Iss. 2, pp. 303-317
Open Access | Times Cited: 4
Cardiovascular effects and safety of classic psychedelics
Acile Nahlawi, Leon M. Ptaszek, Jeremy N. Ruskin
Nature Cardiovascular Research (2025)
Closed Access
Deciphering the tripartite interaction of urbanized environment, gut microbiome and cardio-metabolic disease
Avaneesh Shukla, Chanchal Sharma, Md. Zubbair Malik, et al.
Journal of Environmental Management (2025) Vol. 377, pp. 124693-124693
Closed Access
Educational moderation of gender disparities in psychedelic health outcomes
Sean M. Viña
(2025) Vol. 2, Iss. 1
Closed Access
The compulsive eating paradigm: can psychedelics help in treating obesity?
Dhanush Ammineni, Rebecca J. Park
Journal of Eating Disorders (2025) Vol. 13, Iss. 1
Open Access
Minorities’ diminished psychedelic returns: Depression, suicide, distress, and serious mental illness
Sean M. Viña
Drug Science Policy and Law (2025) Vol. 11
Closed Access
Health-Related Behavioral Changes Following the Use of Psychedelics in Naturalistic Settings
Pedro J. Teixeira, Rakesh K. Jain, Andrew Penn, et al.
(2025)
Closed Access
Ayahuasca and Public Health II: Health Status in a Large Sample of Ayahuasca-Ceremony Participants in the Netherlands
Maja Kohek, Genís Oña, Michiel van Elk, et al.
Journal of Psychoactive Drugs (2022) Vol. 55, Iss. 3, pp. 247-258
Open Access | Times Cited: 15
Impact of a Naturalistic Psychedelic Experience on Smoking: A Retrospective Survey
Bruno Roméo, Baptiste Fauvel, Sylvain Déjean, et al.
Journal of Psychoactive Drugs (2023) Vol. 55, Iss. 5, pp. 640-649
Closed Access | Times Cited: 9
Psychedelic-Assisted Psychotherapy and Mindfulness-Based Cognitive Therapy: Potential Synergies
Richard Chambers, Devon Stoliker, Otto Simonsson
Mindfulness (2023) Vol. 14, Iss. 9, pp. 2111-2123
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top